Clinical trials with plants in diabetes mellitus therapy: a systematic review

Biblioteca

Clinical trials with plants in diabetes mellitus therapy: a systematic review

Clinical trials with plants in diabetes mellitus therapy: a systematic review
2021
Acusar erro

Publication sheet

Nome da publicação: Clinical trials with plants in diabetes mellitus therapy: a systematic review

Authors: Diorge Jonatas Marmitt, Mohamad Hesam Shahrajabian, Márcia Inês Goettert, Claudete Rempel

Source: Expert Review of Clinical Pharmacology

Published in: 2021

File type: Artigo de periódico

Kind of study: Revisão

Link to the original

Summary

The chronic metabolic disorder diabetes mellitus is a fast-growing global problem with huge social, health, and economic consequences, having one of the highest morbidities and mortality rates. Prolonged use of many available medications can produce undesirable side effects. Thus, plants appear as an important source of bioactive resources for the discovery of new treatments for diabetes.
Of the 51 clinical trials found, Curcuma longa, Glycine max, Zingiber officinale, Punica granatum, Aloe vera, Momordica charantia are the species with the greatest amount of clinical trials and the attenuation of insulin resistance, decreased fasting blood glucose and glycosylated hemoglobin levels are some of the main mechanisms by which these plants exert hypoglycemic effects. Thus, we speculate that the Clinical Pharmacology should explore the field of plant-based compounds that will keep concentrating the attention of researchers, and therefore, we gathered studies in advanced stages that highlight the role of plants in the diabetes therapy.